Moreover, abnormal activation of AP-1 plays a critical role in Bmi-1+ CSC-mediated HNSCC invasive growth, and targeting the tumor bulk and Bmi-1+ CSCs by combination therapy effectively inhibits HNSCC growth and eliminates metastases [31]. This evidence concerns the gene BMI1 and neoplasm.